Telomerase activation is observed in almost 90% of human cancers but not in normal tissues of somatic origin and thus is a critical step for multistep carcinogenesis. A more thorough understanding of telomerase regulation may provide not only a molecular basis of cancer progression but also as a way to manipulate telomerase activity as a potential therapeutic modality. Recent progress in studies on telomerase regulation has shown that telomerase activation is achieved at various steps, including transcriptional and post-transcriptional levels of the telomerase reverse transcriptase (hTERT) gene. Although a number of potentially important mechanisms of telomerase activation have been proposed, none of the current models can fully explain tumor-speci®c activation of telomerase, suggesting a need for further extensive analysis. This review includes a summary of recent works on telomerase regulation and a discussion of how we can overcome this situation.
Introduction
The maintenance of telomeres, specialized nucleoprotein structures at the ends of chromosome, is essential for chromosome stability (Blackburn, 1991) . Without new synthesis, telomeres undergo progressive shortening with each cell division (Watson, 1972) , and critically short telomeres under threshold lengths trigger either replicative senescence or apoptosis over a considerable number of cell divisions (Allsopp et al., 1992; Harley et al., 1990) . Telomerase is a ribonucleoprotein complex that extends and maintains the telomeres, and activation of this enzyme is therefore required for cells to overcome replicative senescence and obtain the ability to divide without limits (Counter et al., 1992; Greider and Blackburn, 1989) . This concept was supported by ®ndings that telomerase activity is observed in the vast majority of cancers or cancer cell lines but not in most normal tissues (Kim et al., 1994; Shay and Bacchetti, 1997) . Studies of the telomerase enzyme complex have revealed the presence of two major subunits contributing to enzymatic activity: a structural RNA component (hTER) that contains a template region that binds the TTAGGG repeats in telomeres (Feng et al., 1995) and a catalytic subunit with reverse transcriptase activity (hTERT) (Meyerson et al., 1997; Nakamura et al., 1997) . Puri®ed hTERT mixed with hTR is sucient to reconstitute telomerase activity in vitro (Masutomi et al., 2000) . While hTER is constitutively present in normal and cancer cells, expression of hTERT is almost exclusively limited to cancer cells (Meyerson et al., 1997; Nakamura et al., 1997) . Introduction of the hTERT gene into telomerase-negative normal cells is sucient to induce telomerase activity and to immortalize cells that can be propagated to telomerebased replicative senescence (Bodnar et al., 1998; Nakayama et al., 1998; . Telomerase activity and hTERT mRNA expression are tightly associated in human cancers . In vitro transformation of telomerase-negative normal cells using de®ned genetic elements almost always requires hTERT expression (Hahn et al., 1999) . These ®ndings indicate that hTERT expression is a rate-limiting step in telomerase activity and carcinogenesis.
Elucidation of the mechanisms governing telomerase activation will likely have wide-ranging eects on the study and treatment of cancers. However, the precise molecular mechanisms of telomerase activation and hTERT expression in cancers remain largely unclear, despite the extensive eorts of a number of research groups attempting to dissect such mechanisms. In this review, these works will be summarized and followed by a discussion of the potential applications of this knowledge to cancer therapy.
When is telomerase activated during carcinogenesis?
It is not fully resolved when telomerase is activated during carcinogenesis. Studies of clinical samples have revealed telomerase activation not only in cancers but also in some types of premalignant lesions, such as cervical intraepithelial neoplasia (Kyo et al., 1996; Snijders et al., 1998) , prostate intraepithelial neoplasia (Zhang et al., 1998) , and even some benign lesions, suggesting that telomerase activation is an early event in carcinogenesis. However, in general, levels of telomerase activity in these lesions are low compared to those in cancers , creating some doubt as to the biological signi®cance of this activity. There are some controversies regarding the correlations between the clinico-pathological characteristics of cancers and telomerase activity. Some studies showed increased frequency or levels of telomerase activity in cancers with advanced stages or metastatic phenotypes (Hiyama et al., 1995a (Hiyama et al., , 1996 Clark et al., 1997) , indicating that telomerase activation is a rather late event in cancer progression, while others have failed to observe such correlations. There is thus confusion regarding the points at which telomerase is activated during carcinogenesis.
The role and timing of telomerase activation in carcinogenesis has been well analysed by TERC knockout mouse studies. mTERC null mice exhibit signi®cant telomere erosions, an age-and generation-dependent increase in cytogenic abnormalities, providing evidence that telomere dysfunction with critically short telomeres causes genomic instability (Rudolph et al., 1999) . This concept is further supported by studies of mTERC 7/7 p537/7 double-knockout mice . These mouse cells show high levels of genomic instability exempli®ed by the increased formation of dicentric chromosomes and increased susceptibility to transformation by oncogenes. These mice exhibit signi®cant decreases in tumor latency and overall survival. Thus, in the absence of genome checkpoint functions, telomere dysfunction accelerates genomic instability, which facilitates cancer initiation. According to this concept, it is possible that genomic instability caused by telomere dysfunction occurs in the early stages of carcinogenesis, when telomerase has not yet been activated. During subsequent progression, telomeres in these initiated cells undergo further progressive shortening, generating rampant chromosomal instability, which threatens the survival of these cells. Therefore, telomerase activation necessarily occurs at this stage to stabilize the genome and confer unlimited proliferative capacity upon the emerging and evolving cancer cell.
Telomerase activity in normal cells
Not only cancer cells, but some types of normal cells express telomerase activity, including hematopoietic . ERE: estrogen responsive element. DR3': degenerated vitamin D3 receptor/retinoid X receptor binding site. WT1: Wilms' tumor 1 tumor suppressor gene product. (b) Possible regulatory mechanisms of telomerase activity at various steps progenitor cells, intestinal crypt cells, endometrial cells and basal layer cells of skin and cervical keratinocytes (Counter et al., 1995; Harle-Bachor and Boukamp, 1996; Hiyama et al., 1995b; Kyo et al., 1997; Yasumoto et al., 1996) . The common feature of these telomerase-positive normal cells is their highly regenerative capacity. These cells exhibit continuous or cyclic regeneration throughout human life. Telomerase activity in these cells is tightly associated with cellular proliferation. In hematopoietic progenitor cells, telomerase activity is weakly detected in the primitive stem cells. However, once these cells undergo ex vivo expansion under mitogenic stimulation, telomerase activity is dramatically increased (Hiyama et al., 1995b) . Human endometrium is a unique tissue that undergoes a cyclic pattern of proliferation, secretory activity and breakdown over an approximately 28-day period. Epithelial glandular cells are the source of telomerase activity in endometrium, and telomerase activity in these cells cyclically changes in a menstrual phase-dependent manner, associated with cellular proliferation . Notably, telomerase activity in proliferative phase endometrium is unexpectedly strong, comparable to the activity observed in endometrial cancer cells (Kyo et al., 1997) .
The physiological roles of this proliferation-dependent telomerase regulation in normal cells remain unclear. During ex vivo expansion of hematopoietic cells, telomere length decreases despite the presence of telomerase activity, suggesting that telomerase activity alone is insucient to completely prevent telomere shortening in these cells (Engelhardt et al., 1997) . However, the rate of base pair loss per population doubling decreases in the presence of telomerase activity during expansion, indicating that telomerase activation may slow down the rate of telomere erosion in these cells. Telomerase activation may thus be an adaptive response to protect excessive telomere loss and possibly may help to extend the proliferative life span of highly regenerative cells.
Which cells are the sources of telomerase activity in these regenerative tissues? Is telomerase activity present in a small subset of cells with stem cell-like characters or in wide-range of more mature cells? Immunohistochemical analysis of human endometrium using hTERT antibody reveals that hTERT is broadly expressed in epithelial glandular cells, preferentially in the proliferative phase (Kyo et al., unpublished data) . These ®ndings support the concept that maturated proliferating cells rather than a small subset of stem-like cells are responsible for telomerase activity in endometrium. In contrast, telomerase activity in hematopoietic cells, is detected only in primitive stem cells, such as CD34 + CD38 + cells or CD34 + CD 7 cells (Hiyama et al., 1995b) . Similarly, telomerase activity in normal human keratinocytes of uterine cervix, is detected in a small subset that expresses predominantly integrin b1 and EGFR (Kunimura et al., 1998) . The spectrum of telomerase-positive normal cells may therefore dier according to tissue types.
The molecular mechanisms of this proliferationdependent telomerase regulation remain unclear. There are several lines of evidence suggesting that factors regulating cell proliferation directly or indirectly also regulates telomerase. This is discussed in the following sections. Telomerase regulation during the cell cycle has been an area of contention. Some studies have suggested cell cycle-dependent regulation of telomerase occurs during S phase (Zhu et al., 1996) . However, subsequent analysis revealed that telomerase activity does not change signi®cantly during progression through the stages of the cell cycle, but is lost when cells exit the cell cycle and enter G0 phase .
How is telomerase regulated?
Of all the constituents of the telomerase complex, hTERT appears to be the key molecule involved in telomerase regulation. Regulation of hTERT expression is achieved at various levels, including transcriptional and post-transcriptional ( Figure 1 ).
(1) Transcriptional regulation of hTERT Transcriptional regulation of hTERT is thought to be the major mechanism of telomerase regulation. The hTERT promoter is a GC-rich, TATA-less promoter (Cong et al., 1999; Horikawa et al., 1999; . Deletion analyses in reporter assays show that the proximal region of the hTERT promoter is responsible for most of the transcriptional activity. Indeed, the 200-bp proximal region, designated as the hTERT core promoter, contains the basal transcriptional activity of hTERT . In the core promoter, multiple E-boxes and Sp1 binding sites are located. c-Myc binds to these E-boxes through heterodimer formation with Max proteins and activates transcription of hTERT (Wu et al., 1999; Greenberg et al., 1999) . This is a direct eect of c-myc that does not require de novo protein synthesis. Mad proteins are antagonists of c-Myc and switching from Myc/Max binding to Mad/Max binding decreases promoter activity of hTERT (Gunes et al., 2000; Kyo et al., 2000; Oh et al., 2000; Xu et al., 2001) . Sp1 is also a key molecule that binds to GC-rich sites on the core promoter and activates hTERT transcription . Cooperative action of c-Myc and Sp1 is required for full activation of hTERT promoter. Overexpression of c-Myc is frequently observed in a wide variety of tumor types, and usually results from chromosome translocation involving the c-Myc genes in addition to gene ampli®cation (Alitalo et al., 1987) . During multistep carcinogenesis using ®broblast lineages transfected with SV40 LT, expression levels of c-Myc and Sp1 correlate with the levels of telomerase activity in dierent stages of transformation . Thus, up-regulation of these critical transcription factors may, at least in part, be involved in telomerase activation during carcinogenesis. Can cancer-speci®c telomerase activation be explained only by c-Myc and Sp1 functions? Although overexpression of the c-Myc gene is observed in a signi®cant proportion of tumors, some tumors lack Myc overexpression despite the presence of telomerase activity. Transfer of a normal chromosome 3 into the breast cancer cells represses hTERT expression without aecting c-Myc or Mad levels, or expression of cMyc target genes (Ducrest et al., 2001) . Sp1 protein is a ubiquitous factor, which is abundant in some types of normal cells, but such cells do not always have high telomerase activity. Thus, up-regulation of these factors is not sucient to explain cancer-speci®c telomerase activation.
Are any other transcription factors involved in telomerase activation? There are several putative binding sites for known transcription factors, including NF-kB and Ap1, in upstream sequences of the hTERT promoter, and mutations in these sites decrease promoter activity, indicating that these factors may be involved in transcriptional activation (Kyo et al., unpublished data) . However, these factors are not cancer-speci®c and do not contribute much to cancerspeci®c hTERT expression.
Several lines of evidence suggest that hTERT expression behaves like a recessive trait. Hybrids between immortal cells with and without telomerase activity, or transfers of single chromosomes or parts of chromosomes from normal diploid cells to breast cancer cells, generate hybrid clones with repressed telomerase, which then subsequently exhibit growth arrest or senescence (Bryan et al., 1995; Cuthbert et al., 1999) . However, some hybrid clones can continue to proliferate with long telomeres. These results suggest that normal cells or telomerase-negative immortal cells contain a gene or genes functioning as telomerase repressors, and the latter maintains telomere length through a dominant mechanism other than telomerase reactivation. Therefore, one hypothesis contends that telomerase repressors may exist in normal cells, which contribute to the silencing of telomerase but their function or expression is lost in tumors, leading to the reactivation of telomerase. Identi®cation of the transcriptional repressors interacting with the hTERT promoter is essential to more fully understand the regulation of telomerase, but few telomerase repressors have been reported so far. In reporter assays, we identi®ed a 400-bp silencer region between 7776 and 7378 of the hTERT promoter (the transcription start site is numbered as +1) (Fujimoto et al., 2000) . The inhibitory eects of this silencer are enhanced by cellular dierentiation. There are multiple binding sites for myeloid-speci®c zinc ®nger protein 2 (MZF-2) within this region, and speci®c binding was con®rmed by gel shift assays, and overexpression of MZF-2 represses promoter activity, while mutation of these sites activates it. MZF-2 may thus be an eector of negative regulation of hTERT (Fujimoto et al., 2000) . However, expression of MZF-2 is broadly observed not only in normal cells, but also in cancer cells, and thus unlikely to represent a speci®c telomerase repressor in normal cells. Another candidates for hTERT repression is the Wilms' tumor 1 tumor suppressor gene product (WT1), isolated using an expression cloning approach using cDNA library prepared from normal human kidney tissues (Oh et al., 1999) . WT1 speci®cally binds to GCGCGGGCG at 7281 (numbering based on the transcription start site determined by CapSite Hunting method ), and mutations in this site dramatically induce reporter gene expression in cells known to express WT1. Overexpression of WT1 signi®cantly inhibits telomerases, suggesting that WT1 may be a transcriptional repressor of hTERT. However, WT 1 gene is expressed in limited cell types, such as the kidney, gonad and spleen, and 293 kidney cells exhibit hTERT mRNA expression despite the presence of endogeneous WT1 protein. The role of WT1 as a repressor therefore seems to be limited.
(2) Alternate splicing of hTERT Alternate splicing of hTERT transcripts appears to have at least some role in telomerase regulation. The hTERT transcript has at least six alternate splicing sites (four insertion sites and two deletion sites), and variants containing both or either of the deletion sites are present during development as well as in a panel of cancer cell lines (Ulaner et al., 1998) . One deletion (b site) and all four insertions cause premature translation terminations, whereas the other deletion (a site) is 36 bp and lies within a reverse transcriptase (RT) motif. However, introduction of splicing variants that contain the a, b or both a and b deletion sites fail to reconstitute telomerase activity in telomerase-negative cells (Yi et al., 2000) , suggesting that alternate splicing may be one mechanism of telomerase regulation. Interestingly, splicing variants that lack the a site function as dominant-negative inhibitors of telomerase causing telomere shortening and eventually cell death (Colgin et al., 2000; Yi et al., 2000) . In an analysis of clinical samples, tumors expressing splicing variants of hTERT have been shown to lack telomerase activity (Ulaner et al., 2000) . However, some normal tissues with hTERT transcripts containing both a and b lack telomerase activity (Ulaner et al., 2000) , suggesting that there are further mechanisms for suppressing telomerase activity downstream of hTERT transcription and mRNA splicing, and these mechanisms have been lost during neoplastic transformation.
(3) Epigenetic regulation of hTERT DNA methylation of promoters for certain genes, such as cell cycle regulators and tumor suppressor genes, is responsible for loss of expression of these genes in some cancers. The presence of a large CpG island with dense GC-rich content in the hTERT promoter suggests that DNA methylation and chromatin structure may play a role in the regulation of hTERT expression. However, a generalized pattern of sitespeci®c or region-speci®c methylation correlating with expression of the hTERT gene has not been identi®ed (Dessain et al., 2000; Devereux et al., 1999) , suggesting that this type of regulation is not a major mechanism involved in telomerase regulation.
Posttranscriptional modi®cations of histones have been implicated in the physiological control of chromatin structure (Stein et al., 2000) . Acetylation of the lysine-residue of nucleosomal histones is assumed to lead to local chromatin decondensation, resulting in increasing accessibility of particular DNA regions for RNA polymerase complexes. Histone acetylation is a dynamic process catalyzed by histone acetyltransferase (HAT) and histone deacetylase (HDAC). Several transcription factors, such as Mad, can repress transcription by recruiting HDACs to speci®c sites in certain promoters (Hassig et al., 1997; Heinzel et al., 1997; Laherty et al., 1997) . HDAC1 also mediates transcriptional repression via the Sp1 binding sites (Doetzlhofer et al., 1999) . Given that the core promoter of hTERT contains both E-box elements that bind to Mad and multiple Sp1 sites, the possibility exists that histone acetylation is involved in transcriptional regulation of hTERT. As expected, HDAC inhibitors can induce hTERT transcription in a variety of normal cells (Cong and Bacchetti, 2000; . The responsive element of the hTERT promoter for this regulation is localized to the proximal 200-bp core promoter region including Eboxes and Sp1 sites . HDAC inhibitor-induced hTERT activation requires intact Sp1 sites but not E-boxes in the promoter, and overexpression of dominant negative form of Sp1 abrogates this regulation . Thus, Sp1, but not Mad, plays a central role in this regulation. Con¯icting data, however, has been published. Dierentiation of leukemia cells involves switching of Myc/ Max to Mad/Max binding to the E-boxes on hTERT promoter, associated with decreased histone acetylation of the hTERT promoter (Xu et al., 2001) . Treatment with HDAC inhibitors facilitates histone acetylation of the hTERT promoter and attenuates dierentiationinduced repression of hTERT transcription. Histone acetylation and deacetylation may therefore mediate Myc/Max and Mad/Max regulation of the hTERT promoter via E-boxes. These studies have been based, however, on regulation analyses using cancer cell lines, and the role of these mechanisms in tumor-speci®c hTERT activation remains unclear. Although HDAC inhibitors can easily activate hTERT transcription in a variety of normal cells, direct evidence has not yet shown that histone deacethylation of the hTERT promoter in normal cells is attenuated during carcinogenesis.
(4) Phosphorylation of hTERT protein
Phosphorylation of hTERT protein may be one mechanism of hTERT activation. Telomerase activity in human breast cancer cells is markedly inhibited by the treatment with protein phosphatase 2A (Li et al., 1997) . Some protein kinases, such as Atk kinase and protein kinase C have been reported to mediate phosphorylation of hTERT protein, leading to telomerase activation (Kang et al., 1999; Li et al., 1998) . A potentially interesting mechanism of telomerase regulation through hTERT phosphorylation linked to nuclear localization of the emzyme has recently been reported in human T-lymphocytes. Induction of telomerase in resting CD 4+ T-cells by anti-CD3 stimulation does not require net hTERT protein increase. During this CD 4+ T cell activation, hTERT is phosphorylated and translocated from the cytoplasm to the nucleus (Liu et al., 2001) . Thus, nuclear translocation of telomerase from a presumably nonfunctional cytosolic location to a physiologically relevant nuclear compartment may be one regulatory mechanism of telomerase function in cells. These studies provide evidence for novel control mechanisms of telomerase activity, independent of hTERT protein levels.
(5) Chaperone-mediated regulation
The Hsp90 chaperone complex, including Hsp90, Hsp70 and p23, is functionally associated with telomerase (Holt et al., 1999) . The Hsp90 chaperone complex is known to facilitate the folding of several reverse transcriptases. In an in vivo reconstitution system for telomerase activity, the addition of puri®ed components of the Hsp90 chaperone complex to extracts from cells with weak telomerase activity signi®cantly increased telomerase activity (Akalin et al., 2001) . A signi®cant portion of telomerase may therefore remain unfolded or unassembled in cells with absent or weak telomerase activity. The addition of the Hsp90 complex would then facilitate telomerase assembly, allowing for enhanced telomerase activity. Interestingly, expression of this chaperone complex is up-regulated during malignant transformation or in advanced cancers compared to surrounding noncancerous tissues (Akalin et al., 2001) , suggesting that up-regulation of the chaperone complex may play roles in the enhanced telomerase activation observed in cancer cells.
Factors and agents that regulate telomerase activity
Most factors capable of regulating telomerase activity are growth-regulatory pathways that facilitate or inhibit cellular proliferation. Since telomerase activity is regulated and linked to cellular proliferation, some cell cycle regulator genes are likely to play important roles in the regulation of telomerase activity through the control of cell proliferation. Nevertheless, some factors directly regulate telomerase, independent of cellular proliferation.
(1) Hormones Several hormones are involved in telomerase regulation. Regulation by sex steroid hormones has been Regulation of telomerase S Kyo and M Inoue extensively analysed. Estrogen activates telomerase in estrogen receptor (ER)-positive cells through the upregulation of hTERT mRNA expression . Degenerated estrogen responsive elements (EREs) are located in the hTERT promoter, which directly binds ER and functions as a cis-acting element in response to estrogen stimulation. Estrogen also activates c-Myc expression in ER-positive cells, contributing to transactivation of hTERT. Thus, estrogen directly and indirectly activates telomerase. Tamoxifen is a non-steroidal anti-estrogen with wide use as an adjuvant therapy for breast cancer. In breast cancer cells, tamoxifen antagonizes estrogen action and inhibits telomerase activity (Aldous et al., 1999) . This inhibitory eect is mediated by ER as the pure ER antagonist, ICI182780, blocks inhibition (Wang et al., unpublished data) . Although the precise mechanism is unknown, tamoxifen competitively antagonizes estrogen binding to ER and/or binds to ER aecting the conformation of this receptor protein. This leads to inhibition of estrogen-induced telomerase activation. Progesterone usually functions as an anti-estrogen in a variety of target tissues. In progesterone receptor (PR)-positive breast cancer cells, the regulation of telomerase by progesterone is complex. Initially, progesterone activates telomerase through up-regulation of hTERT mRNA expression, brought about by transcriptional activation of the hTERT promoter . The transcription factors involved in this regulation remain elusive, but Ras/MEK/ERK signaling pathways may be important. Later, progesterone exhibits the opposite eects, inhibiting telomerase activity through transcriptional repression of hTERT. This downregulation involves induction of p21 expression. Overexpression of p21 leads to inhibition of both telomerase activity and hTERT mRNA expression in PR-positive cells. Blockade of p21 expression using an antisense strategy abrogates progesterone-induced inhibition of telomerase. Thus, p21 may be a mediator of this regulation. It is unclear how p21 inhibits telomerase activity, but it is likely attributable to indirect action through cell cycle arrest. The eects of androgens on telomerase activity have been demonstrated in prostate cancer cells. In androgen-sensitive cell lines, telomerase activity is reduced by androgen deprivation, while treatment with testosterone restores high levels of telomerase activity (Soda et al., 2000) . This eect is not observed in androgen-independent cell lines. Androgen thus activates telomerase in androgensensitive cell lines. However it remains unclear whether this eect is direct or not.
(2) Differentiation inducing agents Some dierentiation-inducing agents can repress telomerase activity in a variety of cancer cells, probably through indirect action via induction of cellular dierentiation. Nevertheless, there is evidence of direct action on telomerase by vitamin D and retinoic acids. A heterodimer formed of the vitamin D 3 receptor (VDR) and the retinoid X receptor (RXR) binds to a speci®c response element known as DR3. DR3 consists of two directly repeated pairs of AGGTGA motifs spaced by three nucleotides (DR3), and modulates the expression of VD3-responsive genes as a cis-element. Notably, the sequence 5'-AGTTCATGGAGTTCA-3' (named DR3') located at 72530 on the hTERT promoter is similar to DR3 . Gel shift analysis have revealed that the heterodimer of VDR and RXR speci®cally binds to this DR3' sequence in response to VD 3 and 9-cis-retinoic acid (RA) stimulation (Ikeda et al., unpublished data) . Treatment of bladder cancer cells with VD 3 and 9-cis-RA leads to a decrease in hTERT promoter activity, which requires intact DR3' sequences, as well as inhibiting both hTERT mRNA expression and telomerase activity (Ikeda et al., unpublished data). These studies suggest that Vitamin D and retinoic acids are potential anti-telomerase agents that directly downregulate hTERT transcription. These agents have been used as anti-cancer drugs for various cancers, including hematological malignancies. Long-term treatment of cancer cells with these agents leads to telomere shortening and growth inhibition, possibly due to the telomere dysfunction (Ikeda et al., unpublished data). These processes outlined above may be novel mechanisms through which these agents exhibit anti-tumor action.
(3) Growth factors
Several growth factors regulate telomerase activity in normal and tumor cells. Most regulation is achieved by indirect actions, but some growth factors may work through direct pathways to regulate telomerase. EGF is a representative growth factor that facilitates proliferation of a variety of cell types. Once EGFR-positive cells are exposed to EGF, telomerase activity is up regulated following activation of hTERT mRNA expression (Maida et al., unpublished data) . This is a rapid eect, observed within 6 h after treatment. No requirement for de novo protein synthesis has been observed, suggesting a direct eect of EGF. There are several lines of evidence that speci®c signal transduction pathways mediate this regulation. A speci®c MEK inhibitor of the Ras/MEK/ERK pathway, abrogates EGF-induced activation of hTERT. In addition, transactivation of hTERT by EGF requires a speci®c promoter element (TTCCTTTCCG) located at 722, a consensus binding motif for Ets proteins, known to be the major target of EGF signaling. These ®ndings suggest that EGF signals utilize the Ras/MEK/ERK pathway to activate hTERT expression. Thus, there may be other signal transduction pathways for telomerase regulation in response to stimulation by various growth factors.
(4) Anticancer agents
Some anticancer drugs modulate telomerase activity. Cisplatin is a representative chemotherapeutic agent that cross-links DNA between guanines. Since telo-meres are composed of guanine-rich sequences, it is possible that cisplatin impairs the telomere structure, leading to the inhibition of telomerase activity. Several clinical reports have demonstrated that chemotherapy with Cisplatin leads to signi®cant inhibition of telomerase activity in tumors. However, these eects are probably indirect, following cell cycle arrest, necrosis or apoptosis caused by the action of Cisplatin. When testicular cancer cell lines are treated with Cisplatin, telomerase activity is signi®cantly inhibited but both a high concentration and an interval of 20 h following drug removal are required (Burger et al., 1997) , suggesting an indirect eect of this agent. At present, no anticancer drug used for cancer chemotherapy seems to directly regulate telomerase activity.
(5) Histone deacetylase inhibitors
The role of histone deacetylase (HDAC) inhibitors in telomerase regulation is complex. In a variety of normal cells without telomerase activity, HDAC inhibitors can induce telomerase activity via upregulation of hTERT mRNA expression (Cong et al., 2000; Takakura et al., 2001) indicating that histone deacetylation is involved in transcriptional silencing of hTERT in normal cells. However, in telomerasepositive cancer cells, these agents do not alter telomerase activity or appear to repress it in higher concentrations . The roles of these agents are therefore unclear. These agents are thought to be potentially eective agents for cancer therapy, based on the ®ndings that HDAC inhibitors can induce growth arrest, dierentiation, and/or apoptotic cell death in a wide variety of cancer cells . It is therefore important to clarify the role of these agents in telomerase regulation in cancer cells. One possible mechanism for their diverse eects in cancer and normal cells may be that telomerase has already been fully activated through various mechanisms, including through histone acetylation of the hTERT promoter. HDAC inhibitors may therefore be unable to induce further telomerase activity. Alternatively, HDAC inhibitors induce p21 WAF1 expression in cancer cells probably through histone-acetylation of the promoter (Sowa et al., 1999; Richon et al., 2000) . This may play an important role in the arrest of cell growth or cellular dierentiation, leading to indirect inhibition of telomerase activity.
(6) Cell cycle regulators Some cell cycle regulators are involved in telomerase regulation. Overexpression of p53 eectively represses telomerase activity through transcriptional down-regulation of hTERT in a variety of cancer cell lines Xu et al., 2000) . This eect is independent of p53-induced apoptosis or induction of the p53 target gene p21 . Even though there are two p53 binding motifs outside the core promoter of hTERT, reporter assays reveal that the core promoter is responsible for this regulation, requiring intact Sp1 binding sites . p53 inhibits Sp1 binding to the core promoter with the formation of a p53-Sp1 complex (Xu et al., 2000) . Therefore, protein ± protein interaction of p53 with Sp1 may play critical roles in this regulation. In addition, p21, p15 and p16 exert some inhibitory eects on telomerase activity, altough these are probably secondary eects following the induction of cell cycle arrest (Fuxe et al., 2000; Kagawa et al., 1999; Sawa et al., 1999) . There are two putative E2F-1-binding sites proximal to the transcriptional start site of the hTERT promoter. Mutation of these sites produce dramatic increases in promoter activity, whereas overexpression of E2F-1 represses it, which requires intact E2F-1-binding sites (Crowe et al., 2001) . Human cancer cell lines stably overexpressing E2F-1 exhibit decreased hTERT mRNA expression and telomerase activity. These ®ndings suggest that E2F-1 possesses an atypical function as a transcriptional repressor of the hTERT gene in human cells.
(7) Oncogenes
The human papillomavirus E6 oncoprotein activates telomerase (Klingelhutz et al., 1996) . This eect is celltype speci®c, observed in mammary epithelial cells or keratinocytes but not in ®broblasts. It is not fully understood how E6 activates telomerase in a cell-type speci®c manner. The ®ndings that E6 can activate the c-Myc promoter (Kinoshita et al., 1997) or that E6 post-transcriptionally activates c-Myc protein expression (Wang et al., 1998) suggest the involvement of cMyc function in this regulation. However, unexpectedly, c-Myc levels in E6-transduced cells are not well correlated with levels of telomerase activity (Gewin and Galloway, 2001; Oh et al., 2001; Veldman et al., 2001) . Reporter assays reveal that the proximal core promoter is responsible for E6-mediated transactivation (Oh et al., 2001; Veldman et al., 2001) . However, this regulation does not require intact c-Myc binding sites in the hTERT promoter. These ®ndings suggest that myc-dependent transactivation is not essential for it. The role of other oncogenes in telomerase regulation is largely unknown.
How can we control telomerase activity?
Several strategies have been proposed to inhibit telomerase activity in cells. Antisense technologies against hTER and hTERT, ribozymes against hTER, and introduction of a dominant negative form of hTERT are the most powerful approaches to directly target telomerase.
Other approaches include the use of antiestrogens, progesterone, vitamin D and retinoic acid that appear to have their own pathways for telomerase inhibition. These agents are widely used as anticancer approaches for some tumors, including endometrial cancers and hematological malignancies. Signal transduction inhibitors may ®nd additional utility as anti-telomerase approaches, as some growth factors use these pathways for telomerase regulation. Several clinical trials using signal transduction inhibitors as novel anticancer drugs are ongoing and are obtaining favorable results in some tumor types. Telomerase is a target for hsp90-mediated assembly of the functional enzyme. Therefore, inhibition of hsp90 function by blocking agents would likely inhibit telomerase, but not in a speci®c manner. Hsp90 blocking agents, such as geldanamycin and its derivatives are touted as anticancer compounds and are currently undergoing clinical trials. However, hsp90 has numerous targets in a given cell, and blanket treatment with hsp90 inhibitors is likely to produce nonspeci®c eects in both normal and cancer cells.
Despite increasing knowledge regarding agents that inhibit telomerase activity, few studies have reported the long-term eects of these agents. If long-term treatment eventually causes telomere dysfunction, leading to chromosomal instability and cell cycle arrest, these agents can be used as speci®c telomerase inhibitors. In such cases, they might be better used as adjuvant therapies, in combination with chemotherapy or radiotherapy. For example, cytotoxic agents might be used ®rst to reduce tumor bulk, then telomerase inhibitors used over a longer period to induce tumor cell death, when telomeric length becomes critically shortened.
Application of hTERT promoter for cancer gene therapy
Recent progress in our understanding of the controlling mechanisms of the hTERT gene has prompted the use of the hTERT promoter for vectors for cancer gene therapy. This strategy is based on the expectation that the hTERT promoter can confer strong tumor-speci®c transgene expression, minimizing toxicity to normal cells. In vitro and in vivo administration of chimeric vectors in which the hTERT promoter is linked to apoptosis-inducing genes, such as caspase, FADD or Bax, successfully induces apoptosis in cancer cells without damaging normal cells (Gu et al., 2000; Komata et al., 2001; Koga et al., 2000) . Notably, the minimal 200-bp core promoter of hTERT is sucient to eectively induce apoptosis. However, one concern is that the hTERT promoter activity in cancer cells may be insucient for eective transgene expression, compared to the universal promoters, such as SV40 or CMV promoter. According to in vitro reporter assays, the transcriptional activity of hTERT is dependent on cell type. In cancer cells with extremely high levels of telomerase activity, hTERT promoter activity is equivalent to that of the SV40 promoter . However, in cancer cells with weak telomerase activity, promoter activity is approximately 10 ± 20% of that of SV40 promoter. Although at present little data exists regarding the minimum levels of promoter activity that is required for ecient expression of transgenes to induce apoptosis or inhibit cell growth, the variation in promoter activity according to cell types should be considered when using the hTERT promoter.
Conclusion
Extensive research on the transcriptional regulation of the hTERT promoter identi®ed several factors, including c-Myc and Sp1, which critically regulate promoter activity. However, most factors are not stringently tumor-speci®c and are also expressed in some normal cells that lack telomerase activity. Thus, tumor-speci®c hTERT expression cannot be explained simply by these transcription factors. Alternatively, tumor-speci®city of hTERT may be explained by unknown`repressors' that are expressed in normal cells but are lost in cancer cells. Unfortunately, such transcriptional repressors have not yet been identi®ed. A number of chromosome transfer experiments have been conducted to identify these repressors, but no chromosome regions able to inhibit hTERT expression in all cell types have been identi®ed. Epigenetic regulation by DNA methylation and histone acetylation is likewise insucient to the task of explaining tumor speci®city of hTERT expression. Studies on phosphorylation and subcellular localization of hTERT may possess the potential to provide a clearer understanding of telomerase regulation. However, antibodies against hTERT, which are indispensable for such studies, have not been well characterized, and their validity and speci®city have not yet been established. Careful evaluation of the results will therefore be required. In summary, despite extensive eorts by a number of groups, the mechanisms of tumor-speci®c telomerase activation are still not established. Further analyses are required to allow a more complete understanding of the regulation of telomerase activity to emerge. Once obtained, such an understanding will provide a solid foundation for further investigation and manipulation of telomerase activity as a potential therapeutic modality.
